The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCIR.L Regulatory News (CIR)

  • There is currently no data for CIR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options

20 May 2022 07:00

RNS Number : 1761M
Circassia Group Plc
20 May 2022
 

Circassia Group plc

("Circassia" or the "Company")

Grant of options

Oxford, UK - 20 May 2022: Circassia Group plc (LSE: CIR) announces that it has granted nominal value options to the Executive Directors over a total of 3,698,277 new ordinary shares in the Company ("Ordinary Shares") under the 2022 Performance Share Plan (the "Options").

The Options will vest on the third anniversary of the date of grant (the "Vesting Date") and are exercisable until the tenth anniversary of the date of grant, subject also to the closing mid-market price of an Ordinary Share either: (a) reaching or exceeding a specified price over a period of 30 consecutive dealing days prior to the Vesting Date or (b) a liquidity event occurring above the specified price (in each case, the "Vesting Level").

33 per cent. of the Options will vest in the event that a Vesting Level of 50p is attained, 66 per cent. of the Options will vest in the event that a Vesting Level of 60p is attained, with 100 per cent. vesting in the event that a Vesting Level of 70p is attained.

The Option awards to each Executive Director are shown below and additional disclosure in relation to PDMR dealing is included at the end of this announcement.

 

Name

Number of shares subject to award

Ian Johnson

1,331,897

Jonathan Emms

1,331,897

Michael Roller

1,034,483

 

Contacts

Circassia

Ian Johnson, Executive Chairman

Michael Roller, Chief Financial Officer

 

+44 (0) 1865 405560

 

 

 

Singer Capital Markets (Nominated Adviser & Broker)

Aubrey Powell / Jen Boorer

 

+44 (0) 20 7496 3000

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

1. Ian Johnson

2. Jonathan Emms

3. Michael Roller

2.

Reason for the notification

a.

Position/status

1. Executive Chairman

2. Chief Operating Officer

3. Chief Financial Officer

b.

Initial notification

/Amendment

 

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Circassia Group plc

b.

LEI

2138006YAT138TOGA556

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Options over Ordinary Shares of 0.08p each.

 

 

GB00BJVD3B28 ISIN for the Ordinary shares

b.

Nature of the transaction

Grant of share options under the 2022 Performance Share Plan over Ordinary Shares in Circassia

 

c.

Price(s) and volume(s)

Price(s)

 

Volume(s)

1. 0.08p

2. 0.08p

3. 0.08p

1. 1,331,897

2. 1,331,897

3. 1,034,483

d.

Aggregated information

· Aggregated volume

· Price

 

 

 

n/a

 

e.

Date of the transaction

19 May 2022

f.

Place of the transaction

Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBLGDUISBDGDC
Date   Source Headline
8th Jul 20195:02 pmRNSHolding(s) in Company
5th Jul 201912:07 pmRNSHolding(s) in Company
2nd Jul 20195:56 pmRNSHolding(s) in Company
2nd Jul 20195:56 pmRNSHolding(s) in Company
2nd Jul 20195:55 pmRNSHolding(s) in Company
1st Jul 20194:55 pmRNSHolding(s) in Company
28th Jun 20197:00 amRNSTotal Voting Rights
25th Jun 20194:57 pmRNSBlock Listing Application
17th Jun 20194:35 pmRNSPrice Monitoring Extension
7th Jun 20196:00 pmRNSHolding(s) in Company
7th Jun 20194:18 pmRNSResult of AGM
6th Jun 20196:23 pmRNSHolding(s) in Company
6th Jun 20194:11 pmRNSHolding(s) in Company
31st May 20197:00 amRNSTotal Voting Rights
28th May 20195:58 pmRNSHolding(s) in Company
28th May 20195:56 pmRNSHolding(s) in Company
21st May 20199:05 amRNSHolding(s) in Company
14th May 20194:24 pmRNSAnnual report and notice of AGM
8th May 20197:00 amRNSPublication of Tudorza Phase IV ASCENT in JAMA
3rd May 20192:18 pmRNSIssue of Equity
1st May 20197:00 amRNSFinal Results
30th Apr 20197:00 amRNSTotal Voting Rights
15th Apr 201911:55 amRNSHolding(s) in Company
1st Apr 20197:00 amRNSFDA approval of Duaklir for treatment of COPD
29th Mar 20194:40 pmRNSSecond Price Monitoring Extn
29th Mar 20194:35 pmRNSPrice Monitoring Extension
29th Mar 20193:58 pmRNSFDA website posts Duaklir NDA approval
29th Mar 20193:34 pmRNSCircassia announces FDA approval of Tudorza sNDA
29th Mar 20197:00 amRNSTotal Voting Rights
5th Mar 20194:53 pmRNSHolding(s) in Company
4th Mar 20194:04 pmRNSHolding(s) in Company
28th Feb 20197:00 amRNSTotal Voting Rights
11th Feb 20195:17 pmRNSHolding(s) in Company
8th Feb 20199:00 amRNSNotice of Results
6th Feb 20194:44 pmRNSHolding(s) in Company
6th Feb 20197:00 amRNSHolding(s) in Company
4th Feb 20195:57 pmRNSHolding(s) in Company
4th Feb 20198:06 amRNSSuccessful FDA Presubmission Meeting for AirNOvent
4th Feb 20198:06 amRNSAdmission to AIM
1st Feb 20194:36 pmRNSPrice Monitoring Extension
1st Feb 20194:03 pmRNSHolding(s) in Company
31st Jan 20197:00 amRNSTotal Voting Rights
30th Jan 20195:30 pmRNSCircassia Pharmaceuticals
30th Jan 20194:41 pmRNSSecond Price Monitoring Extn
30th Jan 20194:35 pmRNSPrice Monitoring Extension
28th Jan 20193:30 pmRNSHolding(s) in Company
28th Jan 20193:30 pmRNSHolding(s) in Company
25th Jan 201911:49 amRNSHolding(s) in Company
24th Jan 20197:00 amRNSCommercial rights acquired from AIT Therapeutics
18th Jan 20192:22 pmRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.